SQA

APRIL 30, 2021

726/2004, 09 March 2021. 726/2004 , which essentially means duplicate MAAs for products authorized via the centralized procedure. World Health Organization (WHO). EC Issues Notice on the Handling of Duplicate Marketing Authorization Applications (MAAs) of Pharmaceutical Products under Article 82(1) of Regulation (EC) No.

COVID-19 Vaccine 52

COVID-19 Vaccine COVID-19 Compliance Governance 52

SQA

DECEMBER 16, 2022

This proposal builds upon the existing legal framework, which came into force in 2002 for blood and 2004 for tissues and cells. It also fosters innovation in this crucial biotech sector. The framework contains parallel provisions for donor selection, quality and safety management and oversight.

FDA 40

FDA Compliance COVID-19 Licensing 40

SQA

OCTOBER 18, 2023

World Health Organization (WHO) Medical Product Alert N o 5/2023: Substandard (Contaminated) Syrup Medicines, 19 July 2023 Medical Product Alert N o 5/2023 refers to a batch of substandard (contaminated) Naturcold Syrup identified in Cameroon and first reported to WHO on 13 March 2023.

FDA 40

FDA Compliance Licensing World Health 40

SQA

OCTOBER 18, 2023

World Health Organization (WHO) Medical Product Alert N o 5/2023: Substandard (Contaminated) Syrup Medicines, 19 July 2023 Medical Product Alert N o 5/2023 refers to a batch of substandard (contaminated) Naturcold Syrup identified in Cameroon and first reported to WHO on 13 March 2023.

FDA 40

FDA Compliance Licensing World Health 40